BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help

Search Results

Documents 1-16 out of 16 found
  Current Search:  shaking: 1, palsy: 40, parkinson: 728, disease: 8804     

HTML
59%
GE Healthcares Application for DaTSCAN Ioflupane I123 Injection Accepted by the FDA for Priority Review
- (NewsRx.com) -- GE Healthcare announced that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.

DaTSCAN is a radiopharmaceutical agent containing...

Pharmacy Choice:  Jun 30 2009 12:33PM
Matching: palsy parkinson disease
Find similar documents
HTML
59%
GE Healthcare??s Application for DaTSCAN? Ioflupane I123 Injection Accepted by the FDA for Priority Revi
GE Healthcare announced that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.

DaTSCAN is a radiopharmaceutical agent containing Ioflupane (I) in...

Pharmacy Choice:  Jun 26 2009 10:47AM
Matching: palsy parkinson disease
Find similar documents
HTML
59%
GE Healthcares Application for DaTSCAN (Ioflupane I123 Injection) Accepted by the FDA for Priority R
GE Healthcare announced today that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.

DaTSCAN is a radiopharmaceutical agent containing Ioflupane ...

Genetic Engineering News:  Jun 3 2009 7:01AM
Matching: palsy parkinson disease
Find similar documents
HTML
59%
GE Healthcares Application for DaTSCAN (Ioflupane I123 Injection) Accepted by the FDA for Priority Review
- GE Healthcare announced today that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.

DaTSCAN is a radiopharmaceutical agent containing Ioflupane...

DiGiTAL50:  Jun 2 2009 8:42PM
Matching: palsy parkinson disease
Find similar documents
HTML
59%
GE Healthcares Application for DaTSCAN„ (Ioflupane I123 Injection) Accepted by the FDA for Priority
GE Healthcare announced today that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.

DaTSCAN is a radiopharmaceutical agent containing Ioflupane ...

Genetic Engineering News:  Jun 2 2009 6:33PM
Matching: palsy parkinson disease
Find similar documents
HTML
59%
GE Healthcare's Application for DaTSCAN (Ioflupane I123 Injection) Accepted by the FDA for Priority Review
PRINCETON, N.J.--(BUSINESS WIRE)--GE Healthcare announced today that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.

DaTSCAN is a...

Yahoo! Canada:  Jun 2 2009 4:49PM
Matching: palsy parkinson disease
Find similar documents
HTML
59%
GE HealthcareEURs Application for DaTSCAN (Ioflupane I123 Injection) Accepted by the FDA for Priority Revi
Company Website: http:www.gehealthcare.com PRINCETON, N.J.

-- (Business Wire) GE Healthcare announced today that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for...

Stockwatch:  Jun 2 2009 4:34PM
Matching: palsy parkinson disease
Find similar documents
HTML
59%
GE Healthcare's Application for DaTSCAN (Ioflupane I123 Injection) Accepted by the FDA for Priority Review
PRINCETON, N.J.--(BUSINESS WIRE)--GE Healthcare announced today that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.

DaTSCAN is a...

Business Wire via Yahoo!:  Jun 2 2009 4:34PM
Matching: palsy parkinson disease
Find similar documents
HTML
59%
GE HealthcareEURs Application for DaTSCAN„ (Ioflupane I123 Injection) Accepted by the FDA for Priori
A priority review designation is intended for drugs that offer major advances in treatment, or provide treatment where no adequate therapy exists.

The FDA's goal is to review and act on 90 percent of NDAs designated as priority review...

Business Wire:  Jun 2 2009 4:29PM
Matching: palsy parkinson disease
Find similar documents
HTML
59%
GE Healthcare's Application for DaTSCAN (Ioflupane I123 Injection) Accepted by the FDA for Priority Review
A priority review designation is intended for drugs that offer major advances in treatment, or provide treatment where no adequate therapy exists.

The FDA's goal is to review and act on 90 percent of NDAs designated as priority review...

Pharma Live:  Jun 2 2009 7:01PM
Matching: palsy parkinson disease
Find similar documents
HTML
59%
GE Healthcare's Application for DaTSCAN(TM) (Ioflupane I123 Injection) Accepted by the FDA for
BusinessWire - GE Healthcare announced today that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.

DaTSCAN is a radiopharmaceutical agent...

Forbes.com:  Jun 2 2009 5:35PM
Matching: palsy parkinson disease
Find similar documents
HTML
59%
GE Healthcare's Application for DaTSCAN(TM) (Ioflupane I123 Injection) Accepted by the FDA for Priority Review
PRINCETON, N.J.--(BUSINESS WIRE)-- GE Healthcare announced today that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.

DaTSCAN is a...

Street Insider:  Jun 2 2009 4:55PM
Matching: palsy parkinson disease
Find similar documents
HTML
59%
GE Healthcare's Application for DaTSCAN(TM) (Ioflupane I123 Injection) Accepted by the FDA for Priority Review
PRINCETON, N.J.--(BUSINESS WIRE)-- GE Healthcare announced today that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.

DaTSCAN is a...

Street Insider:  Jun 2 2009 4:49PM
Matching: palsy parkinson disease
Find similar documents
HTML
59%
GE Healthcare's Application for DaTSCAN(TM) (Ioflupane I123 Injection) Accepted by the FDA for Priority Review
GE Healthcare announced today that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.

DaTSCAN is a radiopharmaceutical agent containing Ioflupane ...

RBC Dain Raushcer:  Jun 2 2009 4:33PM
Matching: palsy parkinson disease
Find similar documents
HTML
59%
GE Healthcare's Application for DaTSCAN (Ioflupane I123 Injection) Accepted by the FDA for Priority Review
PRINCETON, N.J.

- (BUSINESS WIRE) - GE Healthcare announced today that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.

DaTSCAN is a...

NewsBlaze:  Jun 2 2009 4:30PM
Matching: palsy parkinson disease
Find similar documents
HTML
59%
GE Healthcare Says FDA Accepts DaTSCAN New Drug Application for Priority Review - Update
PM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - GE Healthcare, a division of General Electric Co.

(GE: News ), Tuesday said the Food and Drug Administration or FDA has accepted its New Drug Application or NDA for DaTSCAN - Ioflupane I123...

RTTNews.com:  Jun 2 2009 6:40PM
Matching: palsy parkinson disease
Find similar documents


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.